Diphtheria/Tetanus Toxoid combined vaccine(CSL Ltd.)

CUPERTINO, Calif., June 6, 2023 /PRNewswire/ -- New data released today at the American Society of Clinical Oncology (ASCO) Annual Meeting highlighted the application of PathomIQ Inc.'s PATHOMIQ_PRAD AI test to assess the risk for metastasis in non-metastatic castration-resistant prostate cancer (nmCRPC). PathomIQ is a leading provider of AI-enabled solutions that leverage digitized H&E slides to discover novel biomarkers that predict response to therapy, inform drug discovery, de-risk clinical trials and enable precision medicine in clinical practice. PATHOMIQ_PRAD was developed as an AI-enabled prognostic algorithm that predicts the risk of metastasis from Whole Slide Images (WSIs) of H&E-stained core biopsies or radical prostatectomy specimens. Most patients with prostate cancer treated with androgen deprivation therapy (ADT) for progressive disease will experience progression to CRPC. APA (ERLEADA®)* is approved for the treatment of patients with nmCRPC and metastatic castration sensitive prostate cancer (mCSPC). The objective of this study was to determine the risk for metastasis in patients with nmCRPC based on PATHOMIQ_PRAD risk categories. Patients in the Phase 3 SPARTAN clinical trial with available H&E-stained slides from their primary diagnosis were included in this study. The study showed that PATHOMIQ_PRAD score could have prognostic value in identifying patients at high risk of metastatic progression in nmCRPC setting. All patients receiving APA + ADT had significantly improved metastasis-free survival (MSF) compared with patients receiving ADT alone. "We are honored to be collaborating with Janssen and working closely with their team to evaluate H&E-based AI as a potential tool for prognostic risk stratification in nmCRPC patients. Our PATHOMIQ_PRAD AI model has been successfully validated at multiple medical institutions, and we are working to make it clinically available in the near future," said Dr George Wilding, Chief Medical Officer, PathomIQ Inc. The results were shared at the poster session Genitourinary Cancer – Prostate, Testicular, and Penile Abstract #5027, Poster Board #121, "AI-enabled analysis of H&E-stained prostate cancer tissue images: Assessing risk for metastasis prior to apalutamide (APA) treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC)." To learn more about PathomIQ Inc., please visit * ERLEADA (apalutamide) is a product of Janssen Biotech, Inc.

SAN FRANCISCO--( BUSINESS WIRE )-- ArteraAI , the developer of multimodal artificial intelligence-based predictive and prognostic cancer tests, announces new data validating a multimodal AI-derived predictive biomarker, which has been selected as an oral presentation at the 2023 ASCO annual meeting. The biomarker demonstrated the ability to predict the benefit of long-term androgen deprivation therapy (ADT) in men with localized high-risk prostate cancer. In patients with high-risk localized prostate cancer, ADT is considered a cornerstone of treatment, along with radiotherapy. When making treatment decisions, clinicians and patients must consider the duration of therapy, which is known to have a wide range of negative side effects . To help guide a treatment plan that will maximize benefits and minimize risks, predictive biomarkers are needed. The authors of the research, including Dr. Andrew Armstrong, MD, Professor of Medicine and Surgery at Duke University, sought to develop an AI-based predictive biomarker to address this unmet need. “This is the first-ever AI-derived biomarker that can predict clinical benefit from longer-duration therapy,” said Dr. Andrew Armstrong, MD, Professor of Medicine and Surgery at Duke University and lead author of this research. “We are eager for the further development of this biomarker as it could lead to a tool that has the potential to change how clinicians make treatment decisions. Furthermore, it could help save patients from the physical, emotional, and financial burden of a long-term treatment that would not have therapeutic benefit.” Clinical data and histopathology image data from pretreatment prostate biopsy slides were used to train the model to predict the benefit of long-term vs short-term ADT treatment on distant metastasis. Developed using patient data from six randomized, phase 3 NRG/RTOG trials of men receiving RT +/- ADT, the AI-derived predictive biomarker identified 34% of men that could derive similar benefit with short-term ADT, avoiding the side effects of prolonged ADT. Additionally, the model identified 43% of intermediate-risk men who would benefit from long-term ADT. For more information on ArteraAI, visit Artera.ai . About ArteraAI ArteraAI is a leading precision medicine company developing AI tests to personalize cancer therapy. ArteraAI offers an AI-enabled test that is the first of its kind to provide both predictive and prognostic results for patients with localized prostate cancer: ArteraAI Prostate Test. ArteraAI’s multimodal artificial intelligence (MMAI) biomarker test leverages a unique algorithm that assesses digital images from a patient’s biopsy and learns from a patient's clinical data. The AI combines this information to predict whether a patient will benefit from a particular therapy and determine their prognosis and has been validated in many phase 3 randomized trials. ArteraAI Prostate Test is the first test that can both predict therapy benefit and prognosticate long-term outcomes in localized prostate cancer. The test is clinically available through our CLIA-certified laboratory in Jacksonville, Florida and can be ordered online at Artera.ai .